411 related articles for article (PubMed ID: 18161148)
1. [New bone density conservation agents for osteoporosis under research and development: ED-71].
Hagino H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
[No Abstract] [Full Text] [Related]
2. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
[No Abstract] [Full Text] [Related]
3. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
Wada S; Fukawa T; Kamiya S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
[No Abstract] [Full Text] [Related]
4. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Takata S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
[No Abstract] [Full Text] [Related]
5. Bone density vs bone quality: what's a clinician to do?
Licata A
Cleve Clin J Med; 2009 Jun; 76(6):331-6. PubMed ID: 19487553
[TBL] [Abstract][Full Text] [Related]
6. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
Ikeda K; Fukagawa M
Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
[No Abstract] [Full Text] [Related]
7. [Vitamin K2 treatment for osteoporosis: what is the evidence today?].
Ishida Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():409-14. PubMed ID: 18161141
[No Abstract] [Full Text] [Related]
8. [ED-71].
Takahashi F; Tsuji N; Uchiyama Y
Nihon Rinsho; 2004 Feb; 62 Suppl 2():540-7. PubMed ID: 15035187
[No Abstract] [Full Text] [Related]
9. Long-term effect of strontium ranelate treatment on BMD.
Blake GM; Fogelman I
J Bone Miner Res; 2005 Nov; 20(11):1901-4. PubMed ID: 16234961
[No Abstract] [Full Text] [Related]
10. [Osteoporosis in patients with diabetes mellitus].
Yamauchi M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():526-30. PubMed ID: 18161160
[No Abstract] [Full Text] [Related]
11. [Diagnosis and treatment of immobilization osteoporosis].
Inoue D
Nihon Rinsho; 2007 Nov; 65 Suppl 9():514-9. PubMed ID: 18159714
[No Abstract] [Full Text] [Related]
12. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.
Davison KS; Kendler DL; Ammann P; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; McClung MR; Olszynski WP; Yuen CK
Am J Med; 2009 Nov; 122(11):992-7. PubMed ID: 19854322
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis - new treatments and updates.
Honig S
Bull NYU Hosp Jt Dis; 2011; 69(3):253-6. PubMed ID: 22035439
[No Abstract] [Full Text] [Related]
14. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Yamada S; Inaba M; Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
[No Abstract] [Full Text] [Related]
15. [Evidence of alendronate treatment for osteoporosis].
Harada A
Nihon Rinsho; 2007 Nov; 65 Suppl 9():337-43. PubMed ID: 18161127
[No Abstract] [Full Text] [Related]
16. Bone loss in spinal cord-injured patients: from physiopathology to therapy.
Maïmoun L; Fattal C; Micallef JP; Peruchon E; Rabischong P
Spinal Cord; 2006 Apr; 44(4):203-10. PubMed ID: 16158075
[TBL] [Abstract][Full Text] [Related]
17. [Drugs in development for the treatment of osteoporosis: Active vitamin D analog(ED-71)].
Kubodera N; Tsuji N; Uchiyama Y
Nihon Rinsho; 2002 Mar; 60 Suppl 3():517-28. PubMed ID: 11979950
[No Abstract] [Full Text] [Related]
18. [Outline of Guidelines 2004 for bone marker in osteoporosis].
Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():37-41. PubMed ID: 18161079
[No Abstract] [Full Text] [Related]
19. [Role of bone histology in the determination of bone metabolism].
Barthel HR; Seibel MJ
Med Klin (Munich); 2003 Feb; 98(2):111-2; author reply 113. PubMed ID: 12638546
[No Abstract] [Full Text] [Related]
20. How to prevent glucocorticoid-induced osteoporosis.
Dore RK
Cleve Clin J Med; 2010 Aug; 77(8):529-36. PubMed ID: 20682515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
